Pfizer and BioNTech: Vaccine 95% effective in final efficacy analysis of phase 3 trial

Eren Sengezer FXStreet

Pfizer Inc said on Wednesday that the final efficacy analysis of phase 3 trial of the coronavirus vaccine it develops with BioNTech has shown to be 95% effective, as reported by Reuters.

Additional takeaways

"Efficacy of COVID-19 vaccine was consistent across age, race and ethnicity demographics."

"Planning to file for US emergency use authorization of COVID-19 vaccine within days."

"Concluded phase 3 study with 170 confirmed cases of covid; 162 of those cases were in the placebo arm."

"9 of the severe COVID-19 cases were in the placebo group, 1 was in the vaccine group."

"10 severe cases of COVID-19 were observed in the trial."

"Observed efficacy of COVID-19 vaccine in adults over 65 was over 94%."

"No serious safety concerns observed in the COVID-19 vaccine trial."

"Side effects were mostly mild to moderate and cleared up quickly."

"The only significant side effect greater than 2% in frequency was fatigue at 3.7%."

"Still expecting to make up to 50 million doses this year, 1.3 billion in 2021."

Market reaction

The S&P 500 Futures edged higher on this report and was last seen gaining 0.35% on the day at 3,619.

Author

Eren Sengezer

FXStreet

As an economist at heart, Eren Sengezer specializes in the assessment of the short-term and long-term impacts of macroeconomic data, central bank policies and political developments on financial assets.

GBP/USD strengthens to near 1.3400 as UK political risk fades

The GBP/USD pair gathers strength near 1.3395 during the Asian trading hours on Thursday, bolstered by fading domestic political uncertainty. However, hawkish minutes from the Federal Reserve and renewed tensions between the US and Iran might support the US Dollar and cap the upside for the major pair.

EUR/USD sticks to positive bias above 1.1400 vs USD; Mideast tensions cap gains

The EUR/USD pair attracts some buyers for the second straight day, though it lacks follow-through and remains confined within the previous day's range during the Asian session on Thursday. Spot prices currently trade around the 1.1420 area, up less than 0.10% for the day, and remain at the mercy of the US Dollar price dynamics.

Gold keeps the red despite softer USD; stays below $4,100

Gold trades with a mild negative bias in the Asian session on Thursday, fading the overnight bounce from $4,020, or a one-week low. Minutes of the June FOMC meeting showed an evenly divided debate over the monetary policy outlook and failed to impress the US Dollar bulls, which is supporting Gold. However, fresh US-Iran tensions drive Oil higher, reviving inflation concerns and limiting the USD's downside and the bullion's rebound.

Ethereum: Bulls reclaim dominance, but buying remains weak

Ethereum has slowly seen a return of bullish dominance over the past few days after a lengthy period of bearish pressure. However, buying pressure remains weak despite registering nearly a 10% gain since the beginning of the month.

2.50%: Why the Kiwi's first hike in three years is a wager on a number nobody can see

The Reserve Bank of New Zealand (RBNZ) raised the Official Cash Rate (OCR) by 25 basis points to 2.50% at 02:00 GMT on Wednesday, its first hike in three years and the moment the bank that cut deeper than any G10 peer last cycle turned to face the other way.

Bye, forward guidance: How to trade when central banks choose silence

Central banks have spent years telling markets what might come next. Now, traders face the possibility that they say a lot less. From the Federal Reserve to the European Central Bank and the Bank of England, policymakers are pushing back against forward guidance.